Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy

Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy

US Patent 12201719 · Granted Jan 21, 2025

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Use of semaphorin-4D antibodies in combination with an immune modulating therapy2024
Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy2023
Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy2023
Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy2023
Use of semaphorin-4D binding molecules for the treatment of Rett syndrome2023
Treatment of cancer with a semaphorin-4D antibody in combination with an epigene2023
Use of semaphorin-4D inhibitory molecules with an immune modulating therapy to i2021
Identification of immunogenic MHC class II peptides for immune-based therapy2020
Use of anti-semaphorin-4D antibodies in combination with an immune modulating th2020
Use of antibodies or antigen-binding fragments thereof that specifically bind se2017
Combination of SEMA-4D inhibitors and immunomodulators to inhibit tumors and met2016
Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory2014